- Topic
5k Popularity
4k Popularity
37k Popularity
422 Popularity
39k Popularity
9k Popularity
17k Popularity
6k Popularity
3k Popularity
112k Popularity
- Pin
- 🚨 Gate Alpha Ambassador Recruitment is Now Open!
📣 We’re looking for passionate Web3 creators and community promoters
🚀 Join us as a Gate Alpha Ambassador to help build our brand and promote high-potential early-stage on-chain assets
🎁 Earn up to 100U per task
💰 Top contributors can earn up to 1000U per month
🛠 Flexible collaboration with full support
Apply now 👉 https://www.gate.com/questionnaire/6888
- 🔥 Gate Square #Gate Alpha Third Points Carnival# Trading Sharing Event - 5 Days Left!
Share Alpha trading screenshots with #Gate Alpha Trading Share# to split $100!
🎁 10 lucky users * 10 USDT each
📅 July 4, 4:00 – July 20, 16:00 UTC+8
Gate Alpha 3rd Points Carnival Issue 10 is in full swing!
Trade and post for double the chances to win!
Learn more: https://www.gate.com/campaigns/1522alpha?pid=KOL&ch=5J261cdf
- 🎉 [Gate 30 Million Milestone] Share Your Gate Moment & Win Exclusive Gifts!
Gate has surpassed 30M users worldwide — not just a number, but a journey we've built together.
Remember the thrill of opening your first account, or the Gate merch that’s been part of your daily life?
📸 Join the #MyGateMoment# campaign!
Share your story on Gate Square, and embrace the next 30 million together!
✅ How to Participate:
1️⃣ Post a photo or video with Gate elements
2️⃣ Add #MyGateMoment# and share your story, wishes, or thoughts
3️⃣ Share your post on Twitter (X) — top 10 views will get extra rewards!
👉
Global Real-World Study Results of the Largest-scale JAK1 Inhibitor Released
On March 8th, Jinshi Data reported that at the recent AAD meeting in the United States, the interim results of the world's largest JAK1 inhibitor, Abrocitinib, in the real world study AHEAD (Abrocitinib CHinese rEgistry on AD) were internationally released. This provides more real-world research and medical evidence data for the innovative small molecule drug with high selectivity JAK1 inhibitor in the field of atopic dermatitis (AD), further strengthening the clinical scientific basis to optimize treatment strategies and drive the reshaping of AD diagnosis and treatment pathways.